CureVac NV
(NASDAQ:CVAC)
$11.06
-0.62[-5.31%]
At close: Feb 3
$11.06
After Hours: 4:35PM EDT
Day Range11.010 - 11.83052 Wk Range5.630 - 20.500Open / Close11.470 / 11.060Float / Outstanding75.236M / 190.283M
Vol / Avg.537.147K / 959.793KMkt Cap2.105BP/E-50d Avg. Price8.460
Div / Yield (Forward)- / -%Payout Ratio-Total Float75.236MEPS-0.640

CureVac Stock (NASDAQ:CVAC), Quotes and News Summary

CureVac Stock (NASDAQ: CVAC) stock price, news, charts, stock research, profile.

Loading...
Day Range11.010 - 11.83052 Wk Range5.630 - 20.500Open / Close11.470 / 11.060Float / Outstanding75.236M / 190.283M
Vol / Avg.537.147K / 959.793KMkt Cap2.105BP/E-50d Avg. Price8.460
Div / Yield (Forward)- / -%Payout Ratio-Total Float75.236MEPS-0.640
InvestorPlace - Jan 26, 2023, 6:06PM
InvestorsObserver - Jan 26, 2023, 6:53AM
InvestorsObserver - Jan 20, 2023, 10:01AM
TipRanks - Jan 19, 2023, 8:43AM
InvestorPlace - Jan 18, 2023, 3:44PM
InvestorsObserver - Jan 18, 2023, 8:00AM
InvestorPlace - Jan 17, 2023, 2:01PM
InvestorsObserver - Jan 17, 2023, 11:51AM
InvestorsObserver - Jan 13, 2023, 6:19AM
InvestorsObserver - Jan 12, 2023, 5:59AM
InvestorsObserver - Jan 11, 2023, 5:59AM
Seeking Alpha - Jan 10, 2023, 1:05PM
Seeking Alpha - Jan 10, 2023, 8:25AM
InvestorsObserver - Jan 10, 2023, 5:45AM
InvestorsObserver - Jan 9, 2023, 5:46AM
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-04-27
REV
Q3 2022Est.ActualSurprise
EPS-0.270
REV20.370M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy CureVac (CVAC) stock?

A

You can purchase shares of CureVac (NASDAQ: CVAC) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are CureVac's (CVAC) competitors?

A

There are no as such competitors for CureVac.

Q

What is the target price for CureVac (CVAC) stock?

A

The latest price target for CureVac (NASDAQ: CVAC) was reported by UBS on Thursday, January 19, 2023. The analyst firm set a price target for 18.00 expecting CVAC to rise to within 12 months (a possible 62.75% upside). 4 analyst firms have reported ratings in the last year.

Q

Current Stock Price for CureVac (CVAC)?

A

The stock price for CureVac (NASDAQ: CVAC) is $11.06 last updated February 3, 2023 at 9:00 PM UTC.

Q

Does CureVac (CVAC) pay a dividend?

A

There are no upcoming dividends for CureVac.

Q

When is CureVac (NASDAQ:CVAC) reporting earnings?

A

CureVac’s Q4 earnings are confirmed for Thursday, April 27, 2023.

Q

Is CureVac (CVAC) going to split?

A

There is no upcoming split for CureVac.

Q

What sector and industry does CureVac (CVAC) operate in?

A

CureVac is in the Healthcare sector and Biotechnology industry. They are listed on the NASDAQ.

CureVac Stock (NASDAQ:CVAC), Quotes and News Summary

CureVac Stock (NASDAQ: CVAC) stock price, news, charts, stock research, profile.

Loading...
Day Range11.010 - 11.83052 Wk Range5.630 - 20.500Open / Close11.470 / 11.060Float / Outstanding75.236M / 190.283M
Vol / Avg.537.147K / 959.793KMkt Cap2.105BP/E-50d Avg. Price8.460
Div / Yield (Forward)- / -%Payout Ratio-Total Float75.236MEPS-0.640
InvestorPlace - Jan 26, 2023, 6:06PM
InvestorsObserver - Jan 26, 2023, 6:53AM
InvestorsObserver - Jan 20, 2023, 10:01AM
TipRanks - Jan 19, 2023, 8:43AM
InvestorPlace - Jan 18, 2023, 3:44PM
InvestorsObserver - Jan 18, 2023, 8:00AM
InvestorPlace - Jan 17, 2023, 2:01PM
InvestorsObserver - Jan 17, 2023, 11:51AM
InvestorsObserver - Jan 13, 2023, 6:19AM
InvestorsObserver - Jan 12, 2023, 5:59AM
InvestorsObserver - Jan 11, 2023, 5:59AM
Seeking Alpha - Jan 10, 2023, 1:05PM
Seeking Alpha - Jan 10, 2023, 8:25AM
InvestorsObserver - Jan 10, 2023, 5:45AM
InvestorsObserver - Jan 9, 2023, 5:46AM
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-04-27
REV
Q3 2022Est.ActualSurprise
EPS-0.270
REV20.370M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy CureVac (CVAC) stock?

A

You can purchase shares of CureVac (NASDAQ: CVAC) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are CureVac's (CVAC) competitors?

A

There are no as such competitors for CureVac.

Q

What is the target price for CureVac (CVAC) stock?

A

The latest price target for CureVac (NASDAQ: CVAC) was reported by UBS on Thursday, January 19, 2023. The analyst firm set a price target for 18.00 expecting CVAC to rise to within 12 months (a possible 62.75% upside). 4 analyst firms have reported ratings in the last year.

Q

Current Stock Price for CureVac (CVAC)?

A

The stock price for CureVac (NASDAQ: CVAC) is $11.06 last updated February 3, 2023 at 9:00 PM UTC.

Q

Does CureVac (CVAC) pay a dividend?

A

There are no upcoming dividends for CureVac.

Q

When is CureVac (NASDAQ:CVAC) reporting earnings?

A

CureVac’s Q4 earnings are confirmed for Thursday, April 27, 2023.

Q

Is CureVac (CVAC) going to split?

A

There is no upcoming split for CureVac.

Q

What sector and industry does CureVac (CVAC) operate in?

A

CureVac is in the Healthcare sector and Biotechnology industry. They are listed on the NASDAQ.

CureVac Stock (NASDAQ:CVAC), Quotes and News Summary

CureVac Stock (NASDAQ: CVAC) stock price, news, charts, stock research, profile.

Loading...
Day Range11.010 - 11.83052 Wk Range5.630 - 20.500Open / Close11.470 / 11.060Float / Outstanding75.236M / 190.283M
Vol / Avg.537.147K / 959.793KMkt Cap2.105BP/E-50d Avg. Price8.460
Div / Yield (Forward)- / -%Payout Ratio-Total Float75.236MEPS-0.640
InvestorPlace - Jan 26, 2023, 6:06PM
InvestorsObserver - Jan 26, 2023, 6:53AM
InvestorsObserver - Jan 20, 2023, 10:01AM
TipRanks - Jan 19, 2023, 8:43AM
InvestorPlace - Jan 18, 2023, 3:44PM
InvestorsObserver - Jan 18, 2023, 8:00AM
InvestorPlace - Jan 17, 2023, 2:01PM
InvestorsObserver - Jan 17, 2023, 11:51AM
InvestorsObserver - Jan 13, 2023, 6:19AM
InvestorsObserver - Jan 12, 2023, 5:59AM
InvestorsObserver - Jan 11, 2023, 5:59AM
Seeking Alpha - Jan 10, 2023, 1:05PM
Seeking Alpha - Jan 10, 2023, 8:25AM
InvestorsObserver - Jan 10, 2023, 5:45AM
InvestorsObserver - Jan 9, 2023, 5:46AM
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-04-27
REV
Q3 2022Est.ActualSurprise
EPS-0.270
REV20.370M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy CureVac (CVAC) stock?

A

You can purchase shares of CureVac (NASDAQ: CVAC) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are CureVac's (CVAC) competitors?

A

There are no as such competitors for CureVac.

Q

What is the target price for CureVac (CVAC) stock?

A

The latest price target for CureVac (NASDAQ: CVAC) was reported by UBS on Thursday, January 19, 2023. The analyst firm set a price target for 18.00 expecting CVAC to rise to within 12 months (a possible 62.75% upside). 4 analyst firms have reported ratings in the last year.

Q

Current Stock Price for CureVac (CVAC)?

A

The stock price for CureVac (NASDAQ: CVAC) is $11.06 last updated February 3, 2023 at 9:00 PM UTC.

Q

Does CureVac (CVAC) pay a dividend?

A

There are no upcoming dividends for CureVac.

Q

When is CureVac (NASDAQ:CVAC) reporting earnings?

A

CureVac’s Q4 earnings are confirmed for Thursday, April 27, 2023.

Q

Is CureVac (CVAC) going to split?

A

There is no upcoming split for CureVac.

Q

What sector and industry does CureVac (CVAC) operate in?

A

CureVac is in the Healthcare sector and Biotechnology industry. They are listed on the NASDAQ.

CureVac Stock (NASDAQ:CVAC), Quotes and News Summary

CureVac Stock (NASDAQ: CVAC) stock price, news, charts, stock research, profile.

Loading...
Day Range11.010 - 11.83052 Wk Range5.630 - 20.500Open / Close11.470 / 11.060Float / Outstanding75.236M / 190.283M
Vol / Avg.537.147K / 959.793KMkt Cap2.105BP/E-50d Avg. Price8.460
Div / Yield (Forward)- / -%Payout Ratio-Total Float75.236MEPS-0.640
InvestorPlace - Jan 26, 2023, 6:06PM
InvestorsObserver - Jan 26, 2023, 6:53AM
InvestorsObserver - Jan 20, 2023, 10:01AM
TipRanks - Jan 19, 2023, 8:43AM
InvestorPlace - Jan 18, 2023, 3:44PM
InvestorsObserver - Jan 18, 2023, 8:00AM
InvestorPlace - Jan 17, 2023, 2:01PM
InvestorsObserver - Jan 17, 2023, 11:51AM
InvestorsObserver - Jan 13, 2023, 6:19AM
InvestorsObserver - Jan 12, 2023, 5:59AM
InvestorsObserver - Jan 11, 2023, 5:59AM
Seeking Alpha - Jan 10, 2023, 1:05PM
Seeking Alpha - Jan 10, 2023, 8:25AM
InvestorsObserver - Jan 10, 2023, 5:45AM
InvestorsObserver - Jan 9, 2023, 5:46AM
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-04-27
REV
Q3 2022Est.ActualSurprise
EPS-0.270
REV20.370M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy CureVac (CVAC) stock?

A

You can purchase shares of CureVac (NASDAQ: CVAC) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are CureVac's (CVAC) competitors?

A

There are no as such competitors for CureVac.

Q

What is the target price for CureVac (CVAC) stock?

A

The latest price target for CureVac (NASDAQ: CVAC) was reported by UBS on Thursday, January 19, 2023. The analyst firm set a price target for 18.00 expecting CVAC to rise to within 12 months (a possible 62.75% upside). 4 analyst firms have reported ratings in the last year.

Q

Current Stock Price for CureVac (CVAC)?

A

The stock price for CureVac (NASDAQ: CVAC) is $11.06 last updated February 3, 2023 at 9:00 PM UTC.

Q

Does CureVac (CVAC) pay a dividend?

A

There are no upcoming dividends for CureVac.

Q

When is CureVac (NASDAQ:CVAC) reporting earnings?

A

CureVac’s Q4 earnings are confirmed for Thursday, April 27, 2023.

Q

Is CureVac (CVAC) going to split?

A

There is no upcoming split for CureVac.

Q

What sector and industry does CureVac (CVAC) operate in?

A

CureVac is in the Healthcare sector and Biotechnology industry. They are listed on the NASDAQ.

CureVac Stock (NASDAQ:CVAC), Quotes and News Summary

CureVac Stock (NASDAQ: CVAC) stock price, news, charts, stock research, profile.

Loading...
Day Range11.010 - 11.83052 Wk Range5.630 - 20.500Open / Close11.470 / 11.060Float / Outstanding75.236M / 190.283M
Vol / Avg.537.147K / 959.793KMkt Cap2.105BP/E-50d Avg. Price8.460
Div / Yield (Forward)- / -%Payout Ratio-Total Float75.236MEPS-0.640
InvestorPlace - Jan 26, 2023, 6:06PM
InvestorsObserver - Jan 26, 2023, 6:53AM
InvestorsObserver - Jan 20, 2023, 10:01AM
TipRanks - Jan 19, 2023, 8:43AM
InvestorPlace - Jan 18, 2023, 3:44PM
InvestorsObserver - Jan 18, 2023, 8:00AM
InvestorPlace - Jan 17, 2023, 2:01PM
InvestorsObserver - Jan 17, 2023, 11:51AM
InvestorsObserver - Jan 13, 2023, 6:19AM
InvestorsObserver - Jan 12, 2023, 5:59AM
InvestorsObserver - Jan 11, 2023, 5:59AM
Seeking Alpha - Jan 10, 2023, 1:05PM
Seeking Alpha - Jan 10, 2023, 8:25AM
InvestorsObserver - Jan 10, 2023, 5:45AM
InvestorsObserver - Jan 9, 2023, 5:46AM
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-04-27
REV
Q3 2022Est.ActualSurprise
EPS-0.270
REV20.370M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy CureVac (CVAC) stock?

A

You can purchase shares of CureVac (NASDAQ: CVAC) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are CureVac's (CVAC) competitors?

A

There are no as such competitors for CureVac.

Q

What is the target price for CureVac (CVAC) stock?

A

The latest price target for CureVac (NASDAQ: CVAC) was reported by UBS on Thursday, January 19, 2023. The analyst firm set a price target for 18.00 expecting CVAC to rise to within 12 months (a possible 62.75% upside). 4 analyst firms have reported ratings in the last year.

Q

Current Stock Price for CureVac (CVAC)?

A

The stock price for CureVac (NASDAQ: CVAC) is $11.06 last updated February 3, 2023 at 9:00 PM UTC.

Q

Does CureVac (CVAC) pay a dividend?

A

There are no upcoming dividends for CureVac.

Q

When is CureVac (NASDAQ:CVAC) reporting earnings?

A

CureVac’s Q4 earnings are confirmed for Thursday, April 27, 2023.

Q

Is CureVac (CVAC) going to split?

A

There is no upcoming split for CureVac.

Q

What sector and industry does CureVac (CVAC) operate in?

A

CureVac is in the Healthcare sector and Biotechnology industry. They are listed on the NASDAQ.

CureVac Stock (NASDAQ:CVAC), Quotes and News Summary

CureVac Stock (NASDAQ: CVAC) stock price, news, charts, stock research, profile.

Loading...
Day Range11.010 - 11.83052 Wk Range5.630 - 20.500Open / Close11.470 / 11.060Float / Outstanding75.236M / 190.283M
Vol / Avg.537.147K / 959.793KMkt Cap2.105BP/E-50d Avg. Price8.460
Div / Yield (Forward)- / -%Payout Ratio-Total Float75.236MEPS-0.640
InvestorPlace - Jan 26, 2023, 6:06PM
InvestorsObserver - Jan 26, 2023, 6:53AM
InvestorsObserver - Jan 20, 2023, 10:01AM
TipRanks - Jan 19, 2023, 8:43AM
InvestorPlace - Jan 18, 2023, 3:44PM
InvestorsObserver - Jan 18, 2023, 8:00AM
InvestorPlace - Jan 17, 2023, 2:01PM
InvestorsObserver - Jan 17, 2023, 11:51AM
InvestorsObserver - Jan 13, 2023, 6:19AM
InvestorsObserver - Jan 12, 2023, 5:59AM
InvestorsObserver - Jan 11, 2023, 5:59AM
Seeking Alpha - Jan 10, 2023, 1:05PM
Seeking Alpha - Jan 10, 2023, 8:25AM
InvestorsObserver - Jan 10, 2023, 5:45AM
InvestorsObserver - Jan 9, 2023, 5:46AM
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-04-27
REV
Q3 2022Est.ActualSurprise
EPS-0.270
REV20.370M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy CureVac (CVAC) stock?

A

You can purchase shares of CureVac (NASDAQ: CVAC) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are CureVac's (CVAC) competitors?

A

There are no as such competitors for CureVac.

Q

What is the target price for CureVac (CVAC) stock?

A

The latest price target for CureVac (NASDAQ: CVAC) was reported by UBS on Thursday, January 19, 2023. The analyst firm set a price target for 18.00 expecting CVAC to rise to within 12 months (a possible 62.75% upside). 4 analyst firms have reported ratings in the last year.

Q

Current Stock Price for CureVac (CVAC)?

A

The stock price for CureVac (NASDAQ: CVAC) is $11.06 last updated February 3, 2023 at 9:00 PM UTC.

Q

Does CureVac (CVAC) pay a dividend?

A

There are no upcoming dividends for CureVac.

Q

When is CureVac (NASDAQ:CVAC) reporting earnings?

A

CureVac’s Q4 earnings are confirmed for Thursday, April 27, 2023.

Q

Is CureVac (CVAC) going to split?

A

There is no upcoming split for CureVac.

Q

What sector and industry does CureVac (CVAC) operate in?

A

CureVac is in the Healthcare sector and Biotechnology industry. They are listed on the NASDAQ.

CureVac Stock (NASDAQ:CVAC), Quotes and News Summary

CureVac Stock (NASDAQ: CVAC) stock price, news, charts, stock research, profile.

Loading...
Day Range11.010 - 11.83052 Wk Range5.630 - 20.500Open / Close11.470 / 11.060Float / Outstanding75.236M / 190.283M
Vol / Avg.537.147K / 959.793KMkt Cap2.105BP/E-50d Avg. Price8.460
Div / Yield (Forward)- / -%Payout Ratio-Total Float75.236MEPS-0.640
InvestorPlace - Jan 26, 2023, 6:06PM
InvestorsObserver - Jan 26, 2023, 6:53AM
InvestorsObserver - Jan 20, 2023, 10:01AM
TipRanks - Jan 19, 2023, 8:43AM
InvestorPlace - Jan 18, 2023, 3:44PM
InvestorsObserver - Jan 18, 2023, 8:00AM
InvestorPlace - Jan 17, 2023, 2:01PM
InvestorsObserver - Jan 17, 2023, 11:51AM
InvestorsObserver - Jan 13, 2023, 6:19AM
InvestorsObserver - Jan 12, 2023, 5:59AM
InvestorsObserver - Jan 11, 2023, 5:59AM
Seeking Alpha - Jan 10, 2023, 1:05PM
Seeking Alpha - Jan 10, 2023, 8:25AM
InvestorsObserver - Jan 10, 2023, 5:45AM
InvestorsObserver - Jan 9, 2023, 5:46AM
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-04-27
REV
Q3 2022Est.ActualSurprise
EPS-0.270
REV20.370M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy CureVac (CVAC) stock?

A

You can purchase shares of CureVac (NASDAQ: CVAC) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are CureVac's (CVAC) competitors?

A

There are no as such competitors for CureVac.

Q

What is the target price for CureVac (CVAC) stock?

A

The latest price target for CureVac (NASDAQ: CVAC) was reported by UBS on Thursday, January 19, 2023. The analyst firm set a price target for 18.00 expecting CVAC to rise to within 12 months (a possible 62.75% upside). 4 analyst firms have reported ratings in the last year.

Q

Current Stock Price for CureVac (CVAC)?

A

The stock price for CureVac (NASDAQ: CVAC) is $11.06 last updated February 3, 2023 at 9:00 PM UTC.

Q

Does CureVac (CVAC) pay a dividend?

A

There are no upcoming dividends for CureVac.

Q

When is CureVac (NASDAQ:CVAC) reporting earnings?

A

CureVac’s Q4 earnings are confirmed for Thursday, April 27, 2023.

Q

Is CureVac (CVAC) going to split?

A

There is no upcoming split for CureVac.

Q

What sector and industry does CureVac (CVAC) operate in?

A

CureVac is in the Healthcare sector and Biotechnology industry. They are listed on the NASDAQ.

CureVac Stock (NASDAQ:CVAC), Quotes and News Summary

CureVac Stock (NASDAQ: CVAC) stock price, news, charts, stock research, profile.

Loading...
Day Range11.010 - 11.83052 Wk Range5.630 - 20.500Open / Close11.470 / 11.060Float / Outstanding75.236M / 190.283M
Vol / Avg.537.147K / 959.793KMkt Cap2.105BP/E-50d Avg. Price8.460
Div / Yield (Forward)- / -%Payout Ratio-Total Float75.236MEPS-0.640
InvestorPlace - Jan 26, 2023, 6:06PM
InvestorsObserver - Jan 26, 2023, 6:53AM
InvestorsObserver - Jan 20, 2023, 10:01AM
TipRanks - Jan 19, 2023, 8:43AM
InvestorPlace - Jan 18, 2023, 3:44PM
InvestorsObserver - Jan 18, 2023, 8:00AM
InvestorPlace - Jan 17, 2023, 2:01PM
InvestorsObserver - Jan 17, 2023, 11:51AM
InvestorsObserver - Jan 13, 2023, 6:19AM
InvestorsObserver - Jan 12, 2023, 5:59AM
InvestorsObserver - Jan 11, 2023, 5:59AM
Seeking Alpha - Jan 10, 2023, 1:05PM
Seeking Alpha - Jan 10, 2023, 8:25AM
InvestorsObserver - Jan 10, 2023, 5:45AM
InvestorsObserver - Jan 9, 2023, 5:46AM
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-04-27
REV
Q3 2022Est.ActualSurprise
EPS-0.270
REV20.370M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy CureVac (CVAC) stock?

A

You can purchase shares of CureVac (NASDAQ: CVAC) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are CureVac's (CVAC) competitors?

A

There are no as such competitors for CureVac.

Q

What is the target price for CureVac (CVAC) stock?

A

The latest price target for CureVac (NASDAQ: CVAC) was reported by UBS on Thursday, January 19, 2023. The analyst firm set a price target for 18.00 expecting CVAC to rise to within 12 months (a possible 62.75% upside). 4 analyst firms have reported ratings in the last year.

Q

Current Stock Price for CureVac (CVAC)?

A

The stock price for CureVac (NASDAQ: CVAC) is $11.06 last updated February 3, 2023 at 9:00 PM UTC.

Q

Does CureVac (CVAC) pay a dividend?

A

There are no upcoming dividends for CureVac.

Q

When is CureVac (NASDAQ:CVAC) reporting earnings?

A

CureVac’s Q4 earnings are confirmed for Thursday, April 27, 2023.

Q

Is CureVac (CVAC) going to split?

A

There is no upcoming split for CureVac.

Q

What sector and industry does CureVac (CVAC) operate in?

A

CureVac is in the Healthcare sector and Biotechnology industry. They are listed on the NASDAQ.

CureVac Stock (NASDAQ:CVAC), Quotes and News Summary

CureVac Stock (NASDAQ: CVAC) stock price, news, charts, stock research, profile.

Loading...
Day Range11.010 - 11.83052 Wk Range5.630 - 20.500Open / Close11.470 / 11.060Float / Outstanding75.236M / 190.283M
Vol / Avg.537.147K / 959.793KMkt Cap2.105BP/E-50d Avg. Price8.460
Div / Yield (Forward)- / -%Payout Ratio-Total Float75.236MEPS-0.640
InvestorPlace - Jan 26, 2023, 6:06PM
InvestorsObserver - Jan 26, 2023, 6:53AM
InvestorsObserver - Jan 20, 2023, 10:01AM
TipRanks - Jan 19, 2023, 8:43AM
InvestorPlace - Jan 18, 2023, 3:44PM
InvestorsObserver - Jan 18, 2023, 8:00AM
InvestorPlace - Jan 17, 2023, 2:01PM
InvestorsObserver - Jan 17, 2023, 11:51AM
InvestorsObserver - Jan 13, 2023, 6:19AM
InvestorsObserver - Jan 12, 2023, 5:59AM
InvestorsObserver - Jan 11, 2023, 5:59AM
Seeking Alpha - Jan 10, 2023, 1:05PM
Seeking Alpha - Jan 10, 2023, 8:25AM
InvestorsObserver - Jan 10, 2023, 5:45AM
InvestorsObserver - Jan 9, 2023, 5:46AM
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-04-27
REV
Q3 2022Est.ActualSurprise
EPS-0.270
REV20.370M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy CureVac (CVAC) stock?

A

You can purchase shares of CureVac (NASDAQ: CVAC) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are CureVac's (CVAC) competitors?

A

There are no as such competitors for CureVac.

Q

What is the target price for CureVac (CVAC) stock?

A

The latest price target for CureVac (NASDAQ: CVAC) was reported by UBS on Thursday, January 19, 2023. The analyst firm set a price target for 18.00 expecting CVAC to rise to within 12 months (a possible 62.75% upside). 4 analyst firms have reported ratings in the last year.

Q

Current Stock Price for CureVac (CVAC)?

A

The stock price for CureVac (NASDAQ: CVAC) is $11.06 last updated February 3, 2023 at 9:00 PM UTC.

Q

Does CureVac (CVAC) pay a dividend?

A

There are no upcoming dividends for CureVac.

Q

When is CureVac (NASDAQ:CVAC) reporting earnings?

A

CureVac’s Q4 earnings are confirmed for Thursday, April 27, 2023.

Q

Is CureVac (CVAC) going to split?

A

There is no upcoming split for CureVac.

Q

What sector and industry does CureVac (CVAC) operate in?

A

CureVac is in the Healthcare sector and Biotechnology industry. They are listed on the NASDAQ.